Le Lézard
Classified in: Health
Subject: FDA

FDA Accepts Recros Medica De Novo Submission for Nuvellustm Focal Contouring System

SAN DIEGO, May 7, 2019 /PRNewswire/ -- Recros Medica, Inc. announced today that its de novo regulatory submission for the Nuvellustm Focal Contouring System has been accepted for review by the US Food and Drug Administration (FDA). Nuvellus utilizes the company's proprietary Rotational Fractional Resection (RFR) technology and may provide medical aesthetic physicians a minimally-invasive single treatment option to improve submental (neck and jowl) contouring.

Based on anticipated regulatory timelines, Recros expects to receive FDA clearance in Q4 2019.1 Following FDA clearance, Recros plans to launch Nuvellus to select medical aesthetic experts, with a broader market rollout to follow.

Nuvellus is a novel alternative to current skin contouring approaches such as traditional surgery and energy-based devices. The Nuvellus system will be comprised of an integrated console, reusable surgical handpiece and differentiated consumable attachments for specific contouring applications.

"The entire Recros Medica team is excited about bringing our novel Nuvellus system to aesthetic physicians, and today's submission represents a critical step in that journey," commented Tom Albright, CEO of Recros Medica. "We are confident that Nuvellus will offer customers significant efficacy and versatility, and look forward to working with the FDA to achieve commercial clearance and introduce Nuvellus for one of the largest unmet needs in aesthetic medicine."

About De Novo Submission
The FDA's de novo submission program is used to expedite regulatory review and ensure accurate classification of medical devices with low-to-moderate risk profiles and no comparable, predicate devices in market. To learn more about de novo submission guidelines, please visit www.fda.gov.

About Recros Medica, Inc.
Recros Medica, a privately held company, was co-founded in 2014 by Edward Knowlton, MD, a board-certified plastic surgeon who invented Thermage® and the Viveve System. Dr. Knowlton's newest invention, Rotational Fractional Resection, is a platform technology for use by dermatologists, plastic surgeons and other aesthetic physicians to reduce skin laxity and enhance focal aesthetic contouring. For more information, visit https://www.recrosmedica.com.

Shannon Severino

1 Regulatory submission timelines are determined based on the most up-to-date information at time of publication, and are subject to change.            

SOURCE Recros Medica, Inc.

These press releases may also interest you

at 18:07
Select MultiGen Diagnostics, LLC, an affiliated company of Select Laboratory Partners, Inc., located in Greensboro, NC, will participate in a research study conducted by  Teaching Hospital, Jaffna, and the Tellipalai Trail Cancer Hospital, Sri...

at 18:05
NTT Research, Inc., a division of NTT (TYO:9432), today announced that its Medical and Health Informatics (MEI) Lab has entered a joint research agreement with the Technical University of Munich (TUM) to work on three-dimensionally transformable and...

at 18:05
The report predicts the global dental consumables market to grow with a CAGR of 5.1% over the forecast period from 2019-2025. The study on dental consumables market covers the analysis of the leading geographies such as North America, Europe,...

at 18:04
Laboratory for Advanced Medicine, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced that it will be presenting new data supporting its methylation-based liver cancer...

at 17:58
RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies to improve outcomes for cancer and serious autoimmune disease patients, today announced the appointment of Rakesh Verma, Ph.D., as the Company's...

at 17:45
The "Global Immuno-Oncology Market Demand Analysis & Opportunity Evaluation, 2019-2027" report has been added to ResearchAndMarkets.com's offering. The global immuno-oncology treatment market reached USD 53,859.48 million in 2018 and is expected to...

News published on 7 may 2019 at 14:32 and distributed by: